丁苯酞软胶囊联合尼莫地平片治疗血管性认知障碍的临床观察

Clinical observation on the treatment of vascular cognitive impairment with butylphthalide soft capsules and nimodipine

目的观察丁苯酞软胶囊联合尼莫地平片治疗血管性认知障碍(VCI)的临床效果.方法收集2019年1月~2020年1月收治的90例VCI患者的临床资料,根据治疗方案不同分为对照组(n=48,给予尼莫地平片治疗)与观察组(n=42,给予丁苯酞软胶囊治疗),对比两组蒙特利尔认知评估量表(MoCA)评分、日常生活能力量表(ADL)评分和临床疗效.结果两组MoCA、ADL评分治疗前无明显差异(P>0.05),但观察组治疗后MoCA、ADL评分与对照组相比明显较高(P<0.05);观察组治疗后的临床有效率与对照组相比明显较高(P<0.05);两组治疗期间均未出现心肝肾等不良反应.结论丁苯酞软胶囊联合尼莫地平片治疗VCI均安全可靠,但前者疗效更显著,对患者认知功能、生活能力的改善效果更突出.

Objective To observe the clinical effect of butylphthalide soft capsules and nimodipine in the treatment of vascular cognitive impairment(VCI).Met hods The clinical data of 90 patients with VCI admitted between January 2019 and January 2020 were collected.The patients were divided into control group(n=48,treated with nimodipine)and observation group(n=42,treated with butylphthalide soft capsules).The Montreal Cognitive Assessment(MoCA)scores,activities of daily living scale(ADL)scores and clinical effect were compared between the two groups.Results There was no significant difference in MoCA scores or ADL scores between the two groups before treatment(P<0.05).After treatment,the above scores of the observation group were significantly higher than the control group(P<0.05).The clinical effective rate in the observation group was significantly higher than the control group(P<0.05).There were no adverse reactions in either group during treatment.Conclusion Butylphthalide soft capsules and nimodipine are safe and reliable in the treatment of VCI,hut the former is more effective and the improvement of patients'cognitive function and living ability is more obvious.